Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration.
Jonathan
J
Kimmelman
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy; D002986:Clinical Trials as Topic; D016527:Drug Costs; D019317:Evidence-Based Medicine; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D005791:Patient Care / Q000592:standards; D010817:Physician-Patient Relations / Q000941:ethics; D000069579:Ranibizumab; D013810:Therapeutic Equivalency; D014342:Truth Disclosure; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab